| Literature DB >> 26447777 |
Miriam Rabkin1, Anthony Mutiti2, Christine Chung3, Yuan Zhang4, Ying Wei4, Wafaa M El-Sadr1.
Abstract
We assessed cardiovascular disease (CVD) risk factor prevalence and risk stratification amongst adults on antiretroviral therapy in South Africa. Of the 175 patients screened, 37.8% had high blood pressure (HBP), 15.4% were current smokers, 10.4% had elevated cholesterol, and 4.1% had diabetes, but very few (3.6%) had a 10-year CVD risk >10%. One-third of those with HBP, 40% of those with diabetes, and two-thirds of those with high cholesterol had not previously been diagnosed. Although participants were adherent with chronic HIV care, screening for and management of CVDRF were suboptimal, representing a missed opportunity to reduce non-AIDS morbidity and mortality.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26447777 PMCID: PMC4598081 DOI: 10.1371/journal.pone.0140298
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Participant Demographics, Health History, and CVD RF Prevalence.
| All (N = 175) | Female (N = 130) | Male(N = 45) | ||
|---|---|---|---|---|
|
|
| |||
| Sex, female | 130 (74.2%) | |||
| Age, mean (SD) | 45.4 (8.8) | 44.7 (9.0) | 47.6 (7.9) | |
| Population group |
| 173 (98.9%) | 128 (98.5%) | 45 (100%) |
| Marital status |
| 56 (32.0%) | 34 (26.2%) | 22 (48.9%) |
| Educational attainment |
| 66 (37.9%) | 41 (31.5%) | 25 (55.6%) |
|
| 75 (43.1%) | 61 (46.9%) | 14 (31.1%) | |
| Household has electricity | 158 (90.3%) | 121 (93.1%) | 37 (82.2%) | |
| Household has piped water | 175 (100%) | 130 (100%) | 45 (100%) | |
|
|
| |||
| Most recent CD4, mean (SD) | 411 (184) | 395 (213) | 322 (175) | |
| Most recent viral load |
| 32 (18.9%) | 30 (23.1%) | 2 (4.4%) |
|
| 94/143 (65.7%) | 67/100 (67.0%) | 27/45 (60.0%) | |
|
| 49/143 (34.3%) | 33/100 (33.0%) | 16/45 (40.0%) | |
|
| 8,693 (26,454) | 4,326 (9,028) | 17,700 (44,012) | |
| On nevirapine or efavirenz | 159 (90.9%) | 119 (90%) | 42 (93.3%) | |
| On protease inhibitor-containing regimen | 0 | 0 | 0 | |
|
| ||||
| Prior diagnosis of hypertension (HTN) documented in chart | 52 (29.9%) | 46 (35.6%) | 6 (13.3%) | |
| Prior diagnosis of diabetes (DM) documented in chart | 7 (4%) | 5 (3.9%) | 2 (4.4%) | |
| Prior diagnosis of high cholesterol/hyperlipidemia documented in chart | 14 (8%) | 13 (10.1%) | 1 (2.2%) | |
| Prior documentation of cigarette smoking (ever documented) | 1 (0.6%) | 0 | 1 (2.2%) | |
| Prior documentation of weight (ever documented) | 173 (99.4%) | 129 (100%) | 44 (97.8%) | |
| Prior diagnosis of obesity documented in chart | 0 | 0 | 0 | |
| High BP documented at most recent visit | Any high BP (SBP | 61 (34.9%) | 46 (35.4%) | 15 (33.3%) |
|
| 41 (23.4%) | 32 (24.6%) | 9 (20%) | |
|
| 20 (11.4%) | 14 (10.8%) | 6 (13.3%) | |
| Of pts with diagnosis of HTN, percent with high BP when last documented | 63.5% | 61% | 83% | |
|
| ||||
| Told of DM by health provider | 14 (8%) | 12 (9.2%) | 2 (4.4%) | |
| Told of HTN by health provider | 56 (32%) | 49 (37.7%) | 7 (15.6%) | |
| Told of high cholesterol by health provider | 5 (2.9%) | 4 (3.1%) | 1 (2.2%) | |
| Told of “heart disease” by health provider | 11 (6.3%) | 10 (7.7%) | 1 (2.2%) | |
| Told of obesity or overweight by health provider | 19 (10.9%) | 17 (13.1%) | 2 (4.4%) | |
|
| ||||
| High BP | Any high BP (SBP | 66 (37.7%) | 50 (38.5%) | 16 (35.6%) |
|
| 41 (23.4%) | 31 (23.8%) | 10 (22.2%) | |
|
| 25 (14.3%) | 19 (14.6%) | 6 (13.3%) | |
| BMI |
| 17 (9.8%) | 8 (6.2%) | 9 (20%) |
|
| 37 (21.1%) | 29 (22.3%) | 8 (17.8%) | |
|
| 50 (28.6%) | 48 (36.9%) | 2 (4.4%) | |
| HbA1c |
| 7 (4.1%) | 6 (4.7%) | 1 (2.2%) |
| Total Cholesterol, mean (SD) in mg/dL |
| 184.8 (41.38) | 188.2 (40.85) | 175.4 (41.65) |
|
| 18 (10.4%) | 15 (11.7%) | 3 (6.6%) | |
| Ever smoked tobacco products (cigarette, cigar, pipe)? | 54 (30.9%) | 16 (12.3%) | 38 (84.4%) | |
| Currently smokes tobacco products (in past 30 days) | 27 (15.4%) | 4 (3.1%) | 23 (51.1%) | |
| Currently smokes tobacco daily | 23 (13%) | 3 (2.3%) | 20 (44.4%) | |
Fig 1shows the results for the 110 participants eligible for stratification, superimposed on the WHO/ISH risk stratification charts for the AFR-E region.